Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenomenal: nal-IRI for HER2-negative breast cancer brain metastases
NCT03328884Phase 2Completed
- Sponsor
- MEDSIR
- Start
- May 2017
- Primary completion
- Aug 2018
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan in breast cancer, brain metastases, sponsored by MEDSIR. Started May 2017; status: completed.
02
Drugs
nanoliposomal irinotecan
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on NCT03328884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03328884.